glp-1 remote patient monitoring software CareValidate Ro launches GLP-1 supply tracker
Description
This unique combination equips GLP-1-T with a multifaceted approach to managing metabolic health
Larkin et al v
In the STEP 1 trial, participants receiving semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks
(PROT-AGE Study Group)
& Xie, B
The risk of hypoglycemia is increased if the drug is used in combination with sulfonylureas or insulin
